Targeted intermittent treatment in chronic schizophrenia

Frontiers in Psychiatry

Volumn 4, Issue MAR, 2013, Pages

  Sfera, Adonis ^a  

^a South Coast Clinical Trials Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE;

ARTICLE; BRAIN SIZE; CLINICAL OBSERVATION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TOLERANCE; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HUMAN; MAINTENANCE DRUG DOSE; NEUROLEPTIC INDUCED SUPERSENSITIVITY PSYCHOSIS; PATIENT COMPLIANCE; PSYCHOSIS; RECURRENT DISEASE; RELAPSE; REMISSION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84877702337     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00013     Document Type: Article

References (17)

1. Chouinard, G., and Jones, B. D. (1980). Neuroleptic induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am. J. Psychiatry 137, 16-21.
2. Chouinard, G., Jones, B. D., and Annable, L. (1978). Neuroleptic-induced supersensitivity psychosis. Am. J. Psychiatry 135, 1409-1410.
3. Ekblom, B., Eriksson, K., and Lindstrom, L. H. (1984). Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl.) 83, 293-294.
4. Gaebel, W., Riesbeck, M., and Wobrock, T. (2011). Schizophrenia guidelines across the world: a selective review and comparison. Int. Rev. Psychiatry 23, 379-387.
5. Harrow, M., and Jobe, T. H. (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollowup study. J. Nerv. Ment. Dis. 195, 406-414.
6. Ho, B. C., Andreasen, N. C., Ziebell, S., Pierson, R., and Magnotta, V. (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 68, 128-137.
7. Kahne, G. J. (1989). Rebound psychoses following the discontinuation of a high potency neuroleptic. Can. J. Psychiatry 34, 227-229.
8. Kane, J. M., Woerner, M., and Sarantakos, S. (1986). Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. J. Clin. Psychiatry 47(Suppl.), 30-33.
9. Llorca, P. M., Vaiva, G., and Lancon, C. (2001). Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Can. J. Psychiatry 46, 87-88.
10. Margolese, H. C., Chouinard, G., Beauclair, L., and Belanger, M. C. (2002). Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychopharmacol. 22, 347-352.
11. Prien, R. F., Gillis, R. D., and Caffey, E. M. (1973). Intermittent pharmacotherapy in chronic schizophrenia. Hosp. Community Psychiatry 24, 317-322.
12. Remington, G., and Kapur, S. (2010). Antipsychotic dosing: how much but also how often? Schizophr. Bull. 36, 900-903.
13. Remington, G. J., Prendergast, P., and Bezchlibnyk-Butler, K. Z. (1997). Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Can. J. Psychiatry 42, 53-57.
14. Samaha, A., Seeman, P., Stewart, J., Rajabi, H., and Kapur, S. (2007). Breakthrough dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 27, 2979-2986.
15. Stip, E., Tourjman, V., Lew, V., Fabian, J., Cormier, H., Landry, P., et al. (1995). "Awakenings" effect with risperidone. Am. J. Psychiatry 152, 1833.
16. Tollefson, G. D., Dellva, M. A., Mattler, C. A., Kane, J. M., Wirshing, D. A., and Kinon, B. J. (1999). Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. J. Clin. Psychopharmacol. 19, 435-443.
17. Yamin, S., and Vaddadi, K. (2010). Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine. Int. Rev. Psychiatry 22, 138-147.